본문 바로가기
KERD
논문KCI 등재

Hepatorenal syndrome: Current concepts and future perspectives

Chan-Young Jung|Jai Won Chang
대한간학회 (The korean Association for the Study of the Liver)|2023.10|Clinical and Molecular Hepatology|제29권 제4호|pp. 891-908

2

조회

0

다운로드

0

인용

0

참고문헌

키워드

BiomarkersAcute kidney injuryLiver cirrhosisHepatorenal syndromeTerlipressin

초록

Hepatorenal syndrome (HRS), a progressive but potentially reversible deterioration of kidney function, remains a major complication in patients with advanced cirrhosis, often leading to death before liver transplantation (LT). Recent updates in the pathophysiology, definition, and classification of HRS have led to a complete revision of the nomenclature and diagnostic criteria for HRS type 1, which was renamed HRS-acute kidney injury (AKI). HRS is characterized by severe impairment of kidney function due to increased splanchnic blood flow, activation of several vasoconstriction factors, severe vasoconstriction of the renal arteries in the absence of kidney histologic abnormalities, nitric oxide dysfunction, and systemic inflammation. Diagnosis of HRS remains a challenge because of the lack of specific diagnostic biomarkers that accurately distinguishes structural from functional AKI, and mainly involves the differential diagnosis from other forms of AKI, particularly acute tubular necrosis. The optimal treatment of HRS is LT. While awaiting LT, treatment options include vasoconstrictor drugs to counteract splanchnic arterial vasodilation and plasma volume expansion by intravenous albumin infusion. In patients with HRS unresponsive to pharmacological treatment and with conventional indications for kidney replacement therapy (KRT), such as volume overload, uremia, or electrolyte imbalances, KRT may be applied as a bridging therapy to transplantation. Other interventions, such as transjugular intrahepatic portosystemic shunt, and artificial liver support systems have a very limited role in improving outcomes in HRS. Although recently developed novel therapies have potential to improve outcomes of patients with HRS, further studies are warranted to validate the efficacy of these novel agents.

Abstract

Hepatorenal syndrome (HRS), a progressive but potentially reversible deterioration of kidney function, remains a major complication in patients with advanced cirrhosis, often leading to death before liver transplantation (LT). Recent updates in the pathophysiology, definition, and classification of HRS have led to a complete revision of the nomenclature and diagnostic criteria for HRS type 1, which was renamed HRS-acute kidney injury (AKI). HRS is characterized by severe impairment of kidney function due to increased splanchnic blood flow, activation of several vasoconstriction factors, severe vasoconstriction of the renal arteries in the absence of kidney histologic abnormalities, nitric oxide dysfunction, and systemic inflammation. Diagnosis of HRS remains a challenge because of the lack of specific diagnostic biomarkers that accurately distinguishes structural from functional AKI, and mainly involves the differential diagnosis from other forms of AKI, particularly acute tubular necrosis. The optimal treatment of HRS is LT. While awaiting LT, treatment options include vasoconstrictor drugs to counteract splanchnic arterial vasodilation and plasma volume expansion by intravenous albumin infusion. In patients with HRS unresponsive to pharmacological treatment and with conventional indications for kidney replacement therapy (KRT), such as volume overload, uremia, or electrolyte imbalances, KRT may be applied as a bridging therapy to transplantation. Other interventions, such as transjugular intrahepatic portosystemic shunt, and artificial liver support systems have a very limited role in improving outcomes in HRS. Although recently developed novel therapies have potential to improve outcomes of patients with HRS, further studies are warranted to validate the efficacy of these novel agents.

참고문헌 (132)

  1. The Korean Association for the Study of the Liver, "KASL clinical practice guidelines for liver cirrhosis: Varices, hepatic encephalopathy, and related complications", Clinical and Molecular Hepatology, 26(2), pp.83~127 (2020), 대한간학회[DOI]
  2. Epstein M, "Hepatorenal syndrome : emerging perspectives of pathophysiology and therapy", J Am Soc Nephrol, 4, pp.1735~1753 (1994)
  3. Arroyo V, "Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club", Hepatology, 23, pp.164~176 (1996)
  4. Salerno F, "Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis", Gut, 56, pp.1310~1318 (2007)
  5. Belcher JM, "Association of AKI with mortality and complications in hospitalized patients with cirrhosis", Hepatology, 57, pp.753~762 (2013)
  6. Piano S, "Evaluation of the Acute Kidney Injury Network criteria in hospitalized patients with cirrhosis and ascites", J Hepatol, 59, pp.482~489 (2013)
  7. Fagundes C, "A modified acute kidney injury classification for diagnosis and risk stratification of impairment of kidney function in cirrhosis", J Hepatol, 59, pp.474~481 (2013)
  8. Tsien CD, "Acute kidney injury in decompensated cirrhosis", Gut, 62, pp.131~137 (2013)
  9. Wong F, "New consensus definition of acute kidney injury accurately predicts 30-day mortality in patients with cirrhosis and infection", Gastroenterology, 145, pp.1280~1288 (2013)
  10. Altamirano J, "Acute kidney injury is an early predictor of mortality for patients with alcoholic hepatitis", Clin Gastroenterol Hepatol, 10, pp.65~71 (2012)
  11. Angeli P, "Acute kidney injury and acute-on-chronic liver failure classifications in prognosis assessment of patients with acute decompensation of cirrhosis", Gut, 64, pp.1616~1622 (2015)
  12. Angeli P, "Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites", Gut, 64, pp.531~537 (2015)
  13. Amathieu R, "Significance of oliguria in critically ill patients with chronic liver disease", Hepatology, 66, pp.1592~1600 (2017)
  14. Angeli P, "News in pathophysiology, definition and classification of hepatorenal syndrome : A step beyond the International Club of Ascites(ICA)consensus document", J Hepatol, 71, pp.811~822 (2019)
  15. Boyer TD, "Predictors of response to terlipressin plus albumin in hepatorenal syndrome (HRS) type 1:relationship of serum creatinine to hemodynamics", J Hepatol, 55, pp.315~321 (2011)
  16. Martín-Llahí M, "Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome:a randomized study", Gastroenterology, 134, pp.1352~1359 (2008)
  17. Albillos A, "Cirrhosis-associated immune dysfunction : distinctive features and clinical relevance", J Hepatol, 61, pp.1385~1396 (2014)
  18. Bernardi M, "Mechanisms of decompensation and organ failure in cirrhosis : From peripheral arterial vasodilation to systemic inflammation hypothesis", J Hepatol, 63, pp.1272~1284 (2015)
  19. Ruiz-del-Arbol L, "Circulatory function and hepatorenal syndrome in cirrhosis", Hepatology, 42, pp.439~447 (2005)
  20. Bernardi M, "Hepatorenal disorders : role of the renin-angiotensin-aldosterone system", Semin Liver Dis, 14, pp.23~34 (1994)
  21. Henriksen JH, "The sympathetic nervous system in liver disease", J Hepatol, 29, pp.328~341 (1998)
  22. Arroyo V, "Renal function abnormalities, prostaglandins, and effects of nonsteroidal antiinflammatory drugs in cirrhosis with ascites. An overview with emphasis on pathogenesis", Am J Med, 81, pp.104~122 (1986)
  23. Nazar A, "LEFT ventricular function assessed by echocardiography in cirrhosis : relationship to systemic hemodynamics and renal dysfunction", J Hepatol, 58, pp.51~57 (2013)
  24. Ruiz-del-Arbol L, "Systemic, renal, and hepatic hemodynamic derangement in cirrhotic patients with spontaneous bacterial peritonitis", Hepatology, 38, pp.1210~1218 (2003)
  25. Ginès P, "Renal failure in cirrhosis", N Engl J Med, 361, pp.1279~1290 (2009)
  26. Fagundes C, "Hepatorenal syndrome : a severe, but treatable, cause of kidney failure in cirrhosis", Am J Kidney Dis, 59, pp.874~885 (2012)
  27. Schroeder ET, "Renal failure in patients with cirrhosis of the liver. 3. Evaluation of intrarenal blood flow by para-aminohippurate extraction and response to angiotensin", Am J Med, 43, pp.887~896 (1967)
  28. Kew MC, "Renal and intrarenal blood-flow in cirrhosis of the liver", Lancet, 2, pp.504~510 (1971)
  29. Sacerdoti D, "Redistribution of renal blood flow in patients with liver cirrhosis. The role of renal PGE2", J Hepatol, 2, pp.253~261 (1986)
  30. Maroto A, "Diagnosis of functional kidney failure of cirrhosis with Doppler sonography : prognostic value of resistive index", Hepatology, 20, pp.839~844 (1994)
  31. Barreto R, "Type-1 hepatorenal syndrome associated with infections in cirrhosis : natural history, outcome of kidney function, and survival", Hepatology, 59, pp.1505~1513 (2014)
  32. Schroeder ET, "Effect of blockade of angiotensin II on blood pressure, renin and aldosterone in cirrhosis", Kidney Int, 9, pp.511~519 (1976)
  33. Moore K, "Plasma endothelin immunoreactivity in liver disease and the hepatorenal syndrome", N Engl J Med, 327, pp.1774~1778 (1992)
  34. Moore KP, "Increased production of cysteinyl leukotrienes in hepatorenal syndrome", J Hepatol, 11, pp.263~271 (1990)
  35. Elia C, "Severe acute kidney injury associated with non-steroidal antiinflammatory drugs in cirrhosis : A case-control study", J Hepatol, 63, pp.593~600 (2015)
  36. Lluch P, "Accumulation of symmetric dimethylarginine in hepatorenal syndrome", Exp Biol Med(Maywood), 231, pp.70~75 (2006)
  37. Nijveldt RJ, "The liver is an important organ in the metabolism of asymmetrical dimethylarginine(ADMA)", Clin Nutr, 22, pp.17~22 (2003)
  38. Nijveldt RJ, "The asymmetrical dimethylarginine(ADMA)-multiple organ failure hypothesis", Clin Nutr, 22, pp.99~104 (2003)
  39. Martin PY, "Nitric oxide as a mediator of hemodynamic abnormalities and sodium and water retention in cirrhosis", N Engl J Med, 339, pp.533~541 (1998)
  40. Nijveldt RJ, "Asymmetrical dimethylarginine(ADMA)in critically ill patients : high plasma ADMA concentration is an independent risk factor of ICU mortality", Clin Nutr, 22, pp.23~30 (2003)
  41. Mindikoglu AL, "Estimation of glomerular filtration rate in patients with cirrhosis by using new and conventional filtration markers and dimethylarginines", Clin Gastroenterol Hepatol, 14, pp.624~632 (2016)
  42. Thabut D, "Model for end-stage liver disease score and systemic inflammatory response are major prognostic factors in patients with cirrhosis and acute functional renal failure", Hepatology, 46, pp.1872~1882 (2007)
  43. Trebicka J, "Addressing profiles of systemic inflammation across the different clinical phenotypes of acutely decompensated cirrhosis", Front Immunol, 10, pp.476~ (2019)
  44. Solé C, "Characterization of inflammatory response in hepatorenal syndrome : Relationship with kidney outcome and survival", Liver Int, 39, pp.1246~1255 (2019)
  45. Wiest R, "Pathological bacterial translocation in liver cirrhosis", J Hepatol, 60, pp.197~209 (2014)
  46. Clària J, "Systemic inflammation in decompensated cirrhosis: Characterization and role in acute-on-chronic liver failure", Hepatology, 64, pp.1249~1264 (2016)
  47. Solé C, "Characterization of inflammatory response in acute-on-chronic liver failure and relationship with prognosis", Sci Rep, 6, pp.32341~ (2016)
  48. Such J, "Nitric oxide in ascitic fluid is an independent predictor of the development of renal impairment in patients with cirrhosis and spontaneous bacterial peritonitis", Eur J Gastroenterol Hepatol, 16, pp.571~577 (2004)
  49. Shah N, "Increased renal expression and urinary excretion of TLR4 in acute kidney injury associated with cirrhosis", Liver Int, 33, pp.398~409 (2013)
  50. Shah N, "Prevention of acute kidney injury in a rodent model of cirrhosis following selective gut decontamination is associated with reduced renal TLR4 expression", J Hepatol, 56, pp.1047~1053 (2012)
  51. Wong F, "Acute kidney injury in liver cirrhosis : new definition and application", Clin Mol Hepatol, 22, pp.415~422 (2016)
  52. Martín-Llahí M, "Prognostic importance of the cause of renal failure in patients with cirrhosis", Gastroenterology, 140, pp.488~496 (2011)
  53. Dudley FJ, "Hepatorenal syndrome without avid sodium retention", Hepatology, 6, pp.248~251 (1986)
  54. Alsaad AA, "Fractional excretion of sodium in hepatorenal syndrome : Clinical and pathological correlation", World J Hepatol, 8, pp.1497~1501 (2016)
  55. Carvounis CP, "Significance of the fractional excretion of urea in the differential diagnosis of acute renal failure", Kidney Int, 62, pp.2223~2229 (2002)
  56. Patidar KR, "Fractional excretion of urea : A simple tool for the differential diagnosis of acute kidney injury in cirrhosis", Hepatology, 68, pp.224~233 (2018)
  57. Han Ah Lee, "Current knowledge about biomarkers of acute kidney injury in liver cirrhosis", Clinical and Molecular Hepatology, 28(1), pp.31~46 (2022), 대한간학회[DOI]
  58. Rafael O. Ximenes, "Early predictors of acute kidney injury in patients with cirrhosis and bacterial infection: urinary neutrophil gelatinase-associated lipocalin and cardiac output as reliable tools", Kidney Research and Clinical Practice, 34(3), pp.140~145 (2015), 대한신장학회
  59. Fagundes C, "Urinary neutrophil gelatinase-associated lipocalin as biomarker in the differential diagnosis of impairment of kidney function in cirrhosis", J Hepatol, 57, pp.267~273 (2012)
  60. Belcher JM, "Kidney biomarkers and differential diagnosis of patients with cirrhosis and acute kidney injury", Hepatology, 60, pp.622~632 (2014)
  61. Huelin P, "Neutrophil gelatinase-associated lipocalin for assessment of acute kidney injury in cirrhosis : A prospective study", Hepatology, 70, pp.319~333 (2019)
  62. Barreto R, "Urinary neutrophil gelatinase-associated lipocalin predicts kidney outcome and death in patients with cirrhosis and bacterial infections", J Hepatol, 61, pp.35~42 (2014)
  63. Gambino C, "Diagnostic and prognostic performance of urinary neutrophil gelatinase-associated lipocalin in patients with cirrhosis and acute kidney injury", Hepatology, 77, pp.1630~1638 (2023)
  64. Allegretti AS, "Urinary NGAL as a diagnostic and prognostic marker for acute kidney injury in cirrhosis: A prospective study", Clin Transl Gastroenterol, 12, pp.e00359~ (2021)
  65. Navasa M, "Tumor necrosis factor and interleukin-6 in spontaneous bacterial peritonitis in cirrhosis : relationship with the development of renal impairment and mortality", Hepatology, 27, pp.1227~1232 (1998)
  66. Sort P, "Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis", N Engl J Med, 341, pp.403~409 (1999)
  67. Salerno F, "Albumin infusion improves outcomes of patients with spontaneous bacterial peritonitis : a meta-analysis of randomized trials", Clin Gastroenterol Hepatol, 11, pp.123~130 (2013)
  68. Fernández J, "Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis", Gastroenterology, 133, pp.818~824 (2007)
  69. Fernández J, "Efficacy of albumin treatment for patients with cirrhosis and infections unrelated to spontaneous bacterial peritonitis", Clin Gastroenterol Hepatol, 18, pp.963~973 (2020)
  70. Guevara M, "Albumin for bacterial infections other than spontaneous bacterial peritonitis in cirrhosis. A randomized, controlled study", J Hepatol, 57, pp.759~765 (2012)
  71. Leão GS, "Albumin for cirrhotic patients with extraperitoneal infections : A metaanalysis", J Gastroenterol Hepatol, 34, pp.2071~2076 (2019)
  72. Caraceni P, "Long-term albumin administration in decompensated cirrhosis (ANSWER): an openlabel randomised trial", Lancet, 391, pp.2417~2429 (2018)
  73. Solà E, "Midodrine and albumin for prevention of complications in patients with cirrhosis awaiting liver transplantation. A randomized placebo-controlled trial", J Hepatol, 69, pp.1250~1259 (2018)
  74. China L, "A randomized trial of albumin infusions in hospitalized patients with cirrhosis", N Engl J Med, 384, pp.808~817 (2021)
  75. "ClinicalTrials.gov identifier: NCT03451292"[URL]
  76. Ki Tae Yoon, "β-blockers in advanced cirrhosis: More friend than enemy", Clinical and Molecular Hepatology, 27(3), pp.425~436 (2021), 대한간학회[DOI]
  77. Kim SG, "Beneficial and harmful effects of nonselective beta blockade on acute kidney injury in liver transplant candidates", Liver Transpl, 23, pp.733~740 (2017)
  78. Villanueva C, "β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension(PREDESCI) : a randomised, double-blind, placebo-controlled, multicentre trial", Lancet, 393, pp.1597~1608 (2019)
  79. Wong RJ, "Assessing the safety of beta-blocker therapy in cirrhosis patients with ascites : A meta-analysis", Liver Int, 39, pp.1080~1088 (2019)
  80. Rodrigues SG, "Beta-blockers in cirrhosis : Evidence-based indications and limitations", JHEP Rep, 2, pp.100063~ (2019)
  81. Kamal F, "Rifaximin for the prevention of spontaneous bacterial peritonitis and hepatorenal syndrome in cirrhosis : a systematic review and meta-analysis", Eur J Gastroenterol Hepatol, 29, pp.1109~1117 (2017)
  82. Peltekian KM, "Cardiovascular, renal, and neurohumoral responses to single large-volume paracentesis in patients with cirrhosis and diuretic-resistant ascites", Am J Gastroenterol, 92, pp.394~399 (1997)
  83. Arora V, "Paracentesis-induced circulatory dysfunction with modest-volume paracentesis is partly ameliorated by albumin infusion in acute-on-chronic liver failure", Hepatology, 72, pp.1043~1055 (2020)
  84. Bhutta AQ, "Beta-blockers in hospitalised patients with cirrhosis and ascites : mortality and factors determining discontinuation and reinitiation", Aliment Pharmacol Ther, 47, pp.78~85 (2018)
  85. Mandorfer M, "Nonselective β blockers increase risk for hepatorenal syndrome and death in patients with cirrhosis and spontaneous bacterial peritonitis", Gastroenterology, 146, pp.1680~1690 (2014)
  86. Uriz J, "Terlipressin plus albumin infusion : an effective and safe therapy of hepatorenal syndrome", J Hepatol, 33, pp.43~48 (2000)
  87. Jamil K, "In vitro binding and receptor-mediated activity of terlipressin at vasopressin receptors V1 and V2", J Exp Pharmacol, 10, pp.1~7 (2017)
  88. Mohamed MMG, "Terlipressin effect on hepatorenal syndrome : Updated meta-analysis of randomized controlled trials", JGH Open, 5, pp.896~901 (2021)
  89. Levitsky J, "Protecting the kidney in liver transplant recipients : Practice-based recommendations from the American Society of Transplantation Liver and Intestine Community of Practice", Am J Transplant, 16, pp.2532~2544 (2016)
  90. European Association for the Study of the Liver, "EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis", J Hepatol, 53, pp.397~417 (2010)
  91. Durand F, "Pathogenesis of hepatorenal syndrome : Implications for therapy", Am J Kidney Dis, 67, pp.318~328 (2016)
  92. Cavallin M, "Terlipressin given by continuous intravenous infusion versus intravenous boluses in the treatment of hepatorenal syndrome : A randomized controlled study", Hepatology, 63, pp.983~992 (2016)
  93. "ClinicalTrials.gov identifier: NCT04460560"[URL]
  94. Cavallin M, "Terlipressin plus albumin versus midodrine and octreotide plus albumin in the treatment of hepatorenal syndrome: A randomized trial", Hepatology, 62, pp.567~574 (2015)
  95. Wong F, "Terlipressin plus albumin for the treatment of type 1 hepatorenal syndrome", N Engl J Med, 384, pp.818~828 (2021)
  96. Piano S, "Response to terlipressin and albumin is associated with improved liver transplant outcomes in patients with hepatorenal syndrome", Hepatology, 73, pp.1909~1919 (2021)
  97. Nazar A, "Predictors of response to therapy with terlipressin and albumin in patients with cirrhosis and type 1 hepatorenal syndrome", Hepatology, 51, pp.219~226 (2010)
  98. Wong F, "Terlipressin improves renal function and reverses hepatorenal syndrome in patients with systemic inflammatory response syndrome", Clin Gastroenterol Hepatol, 15, pp.266~272 (2017)
  99. Piano S, "Association between grade of acute on chronic liver failure and response to terlipressin and albumin in patients with hepatorenal syndrome", Clin Gastroenterol Hepatol, 16, pp.1792~1800 (2018)
  100. Facciorusso A, "Comparative efficacy of pharmacological strategies for management of type 1 hepatorenal syndrome : a systematic review and network meta-analysis", Lancet Gastroenterol Hepatol, 2, pp.94~102 (2017)
  101. European Association for the Study of the Liver, "EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis", J Hepatol, 69, pp.406~460 (2018)
  102. Runyon BA, "Management of adult patients with ascites due to cirrhosis : an update", Hepatology, 49, pp.2087~2107 (2009)
  103. Runyon BA, "Introduction to the revised American Association for the Study of Liver Diseases Practice Guideline management of adult patients with ascites due to cirrhosis 2012", Hepatology, 57, pp.1651~1653 (2013)
  104. Duvoux C, "Effects of noradrenalin and albumin in patients with type I hepatorenal syndrome : a pilot study", Hepatology, 36, pp.374~380 (2002)
  105. Alessandria C, "Noradrenalin vs terlipressin in patients with hepatorenal syndrome : a prospective, randomized, unblinded, pilot study", J Hepatol, 47, pp.499~505 (2007)
  106. Sharma P, "An open label, pilot, randomized controlled trial of noradrenaline versus terlipressin in the treatment of type 1 hepatorenal syndrome and predictors of response", Am J Gastroenterol, 103, pp.1689~1697 (2008)
  107. Singh V, "Noradrenaline vs. terlipressin in the treatment of hepatorenal syndrome : a randomized study", J Hepatol, 56, pp.1293~1298 (2012)
  108. Angeli P, "Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide", Hepatology, 29, pp.1690~1697 (1999)
  109. Sanyal AJ, "A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome", Gastroenterology, 134, pp.1360~1368 (2008)
  110. Boyer TD, "Terlipressin plus albumin is more effective than albumin alone in improving renal function in patients with cirrhosis and hepatorenal syndrome type1", Gastroenterology, 150, pp.1579~1589 (2016)
  111. Arora V, "Terlipressin is superior to noradrenaline in the management of acute kidney injury in acute on chronic liver failure", Hepatology, 71, pp.600~610 (2020)
  112. Gifford FJ, "Systematic review with meta-analysis : vasoactive drugs for the treatment of hepatorenal syndrome type 1", Aliment Pharmacol Ther, 45, pp.593~603 (2017)
  113. Fernández J, "A randomized unblinded pilot study comparing albumin versus hydroxyethyl starch in spontaneous bacterial peritonitis", Hepatology, 42, pp.627~634 (2005)
  114. Brinch K, "Plasma volume expansion by albumin in cirrhosis. Relation to blood volume distribution, arterial compliance and severity of disease", J Hepatol, 39, pp.24~31 (2003)
  115. Bortoluzzi A, "Positive cardiac inotropic effect of albumin infusion in rodents with cirrhosis and ascites : molecular mechanisms", Hepatology, 57, pp.266~276 (2013)
  116. Moreau R, "Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome : a retrospective multicenter study", Gastroenterology, 122, pp.923~930 (2002)
  117. Fernández J, "Effects of albumin treatment on systemic and portal hemodynamics and systemic inflammation in patients with decompensated cirrhosis", Gastroenterology, 157, pp.149~162 (2019)
  118. Lejon S, "Crystal structure and biological implications of a bacterial albumin binding module in complex with human serum albumin", J Biol Chem, 279, pp.42924~42928 (2004)
  119. Mitzner SR, "Improvement of hepatorenal syndrome with extracorporeal albumin dialysis MARS : results of a prospective, randomized, controlled clinical trial", Liver Transpl, 6, pp.277~286 (2000)
  120. Wong F, "Molecular adsorbent recirculating system is ineffective in the management of type 1 hepatorenal syndrome in patients with cirrhosis with ascites who have failed vasoconstrictor treatment", Gut, 59, pp.381~386 (2010)
  121. Jeon You Hyun, "Clinical outcomes and prognostic factors of mortality in liver cirrhosis patients on continuous renal replacement therapy in two tertiary hospitals in Korea", Kidney Research and Clinical Practice, 40(4), pp.687~697 (2021), 대한신장학회[DOI]
  122. Lenhart A, "Chances of renal recovery or liver transplantation after hospitalization for alcoholic liver disease requiring dialysis", Dig Dis Sci, 63, pp.2800~2809 (2018)
  123. Zhang Z, "Role of renal replacement therapy in patients with type 1 hepatorenal syndrome receiving combination treatment of vasoconstrictor plus albumin", J Crit Care, 30, pp.969~974 (2015)
  124. Gupta S, "The role of RRT in hyperammonemic patients", Clin J Am Soc Nephrol, 11, pp.1872~1878 (2016)
  125. Stadlbauer V, "Effect of extracorporeal liver support by MARS and Prometheus on serum cytokines in acute-on-chronic liver failure", Crit Care, 10, pp.R169~ (2006)
  126. Bañares R, "Extracorporeal albumin dialysis with the molecular adsorbent recirculating system in acute-onchronic liver failure: the RELIEF trial", Hepatology, 57, pp.1153~1162 (2013)
  127. Song T, "Transjugular intrahepatic portosystemic shunt for hepatorenal syndrome : A systematic review and meta-analysis", Dig Liver Dis, 50, pp.323~330 (2018)
  128. "HRS-AKI Treatment with TIPS in Patients with Cirrhosis (LiverHERO). ClinicalTrials.gov identifier: NCT05346393"[URL]
  129. srani AK, "Predicting end-stage renal disease after liver transplant", Am J Transplant, 13, pp.1782~1792 (2013)
  130. Formica RN, "Simultaneous liver-kidney allocation policy : A proposal to optimize appropriate utilization of scarce resources", Am J Transplant, 16, pp.758~766 (2016)
  131. Chauhan K, "Pre-liver transplant renal dysfunction and association with post-transplant end-stage renal disease : A singlecenter examination of updated UNOS recommendations", Clin Transplant, 32, pp.e13428~ (2018)
  132. Nadim MK, "Impact of the etiology of acute kidney injury on outcomes following liver transplantation : acute tubular necrosis versus hepatorenal syndrome", Liver Transpl, 18, pp.539~548 (2012)

관련 논문AI추천

Tracking the trajectory of kidney dysfunction in cirrhosis: the acute kidney injury: chronic kidney disease spectrumRakhi Maiwall, Vishnu Girish대한간학회 · Clinical and Molecular Hepatology2025 · 제31권 제3호Current knowledge about biomarkers of acute kidney injury in liver cirrhosisHan Ah Lee, Yeon Seok Seo대한간학회 · Clinical and Molecular Hepatology2022 · 제28권 제1호Albumin for End-Stage Liver Disease이준성대한내과학회 · The Korean Journal of Internal Medicine2012 · 제27권 제1호Prevalence of renal dysfunction in patients with cirrhosis according to ADQI-IAC working party proposal고순영, 구자경, 권소영, 김정한, 양재훈, 이지영, 이창홍, 이초이, 최원혁, 최윤정대한간학회 · Clinical and Molecular Hepatology2014 · 제20권 제2호Pharmacological Interventions for Cirrhotic Ascites: From Challenges to Emerging Therapeutic HorizonsChen Yu, Duan Meili, Gao Yuan, Gao Yunyi, Hou Bing, Liu Xin거트앤리버 소화기연관학회협의회 · Gut and Liver2024 · 제18권 제6호간신증후군이정표대한내과학회 · 대한내과학회지2016 · 제90권 제5호

이 간행물의 다른 논문 (22건)

Critical appraisal of metabolic dysfunction-associated steatotic liver disease: Implication of Janus-faced modernityJoon Ho Moon, 김원, Gi-Ae Kimpp. 831-843Waiting for the changes after the adoption of steatotic liver disease전대원, Eileen L. Yoonpp. 844-850Hepatitis B core-related antigen: A novel and promising surrogate biomarker to guide anti-hepatitis B virus therapyTakako Inoue, Yasuhito Tanaka, Takehisa Watanabepp. 851-868Safety considerations for withdrawal of nucleos(t)ide analogues in patients with chronic hepatitis B: First, do no harmYao-Chun Hsu, Jia-Horng Kao, Cheng-Hao Tsengpp. 869-890The evolving role of lenvatinib at the new era of first-line hepatocellular carcinoma treatmentStephen L. Chan, Landon L. Chanpp. 909-923
원문 보기